NASDAQ
CytoMed Therapeutics Limited (GDTC) has a current ratio of 5.17x as of Monday, May 25, 2026. This represents a 19.58% decrease compared to its 12-month average of 6.42x. The current ratio measures a company's ability to cover short-term obligations by comparing current assets to current liabilities.
No price data available for this timeframe.